Hypercholesterolemia

Results from a prespecified analysis of pooled data from three phase III studies evaluating the safety and efficacy of Inclisiran,...


The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...


The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...


Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ...


Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled...


ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...


Aging is associated with an increased incidence of cancer and cardiovascular disease. Researchers recently used whole-exome sequencing data to identify...


The phase 3 GLAGOV ( GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound )...


Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...


The FDA ( Food and Drug Administration ) has approved the Repatha ( Evolocumab ) Pushtronex system ( on-body infusor...


A reduction of cardiovascular events has been reported in phase 2 and 3 trials of the proprotein convertase subtilisin kexin...


Evolocumab ( Repatha ) is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) that is administered...


The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving...


Lomitapide ( Lojuxta [ EU ], Juxtapid [ US ] ) lowers cholesterol through a different pathway, i.e. through the...


Bococizumab is a humanized monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, which may be a potential therapeutic option for...


Results from ETC-1002-009, a phase 2b study evaluating the efficacy and safety of ETC-1002 ( Bempedoic acid ) compared with...


The FDA ( Food and Drug Administration ) has approved Praluent ( Alirocumab ) injection, the first cholesterol-lowering treatment approved...


Alirocumab ( Praluent ) lowers cholesterol in patients with heterozygous familial hypercholesterolemia to levels unreachable with statins alone, according to...


Efficacy and safety of Alirocumab were compared with Ezetimibe ( Ezetrol, Zetia ) in hypercholesterolemic patients at moderate cardiovascular risk...


Resistant hypertension increases the risk of stroke by 35% in women and 20% in elderly Taiwanese patients, according to research...